When is a Medical Treatment Worth $850,000? The Value of Luxturna and Gene Therapy Treatments: A Health Policy and Bioethics Consortium
Luxturna, a gene therapy treatment for a rare form of inherited blindness, was recently approved and administered for the first time to a patient at Massachusetts Eye and Ear in early 2018 at a cost of $850,000. How should patients, physicians, and the U.S. health care system approach a new generation of gene therapies that offer substantial clinical promise and are made available at such price levels? How do we maximize "health gain" with available resources across the entire population?
This event is free and open to the public, but space is limited and registration is required. Please note that attendees will need to show ID in order to enter the venue. Register now!
Jason I. Comander, MD, PhD, Assistant Professor of Ophthalmology; Associate Director, Inherited Retinal Disorders Service, Massachusetts Eye and Ear
Steven D. Pearson, MD, MSc, President, Institute for Clinical and Economic Review
Moderator: Ameet Sarpatwari, JD, PhD, Assistant Director, Program On Regulation, Therapeutics, and Law (PORTAL), Brigham & Women's Hospital and Instructor in Medicine, Harvard Medical School
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations.
They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.